share_log

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga ·  Feb 27 21:06

Gainers

  • Janux Therapeutics (NASDAQ:JANX) stock rose 120.5% to $33.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion.
  • Viking Therapeutics (NASDAQ:VKTX) shares increased by 97.24% to $75.9. The market value of their outstanding shares is at $7.6 billion.
  • TransMedics Gr (NASDAQ:TMDX) stock rose 22.2% to $95.0. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday.
  • Codexis (NASDAQ:CDXS) shares rose 21.24% to $3.88. The market value of their outstanding shares is at $270.9 million.
  • Ligand Pharmaceuticals (NASDAQ:LGND) shares moved upwards by 20.93% to $90.0. The company's market cap stands at $1.5 billion. The company's, Q4 earnings came out today.
  • Hims & Hers Health (NYSE:HIMS) shares rose 19.5% to $12.25. The company's market cap stands at $2.5 billion. As per the press release, Q4 earnings came out yesterday.

Losers

  • NRX Pharmaceuticals (NASDAQ:NRXP) shares decreased by 22.9% to $0.33 during Tuesday's pre-market session. The company's market cap stands at $28.0 million.
  • Veradigm (NASDAQ:MDRX) shares decreased by 22.03% to $6.48. The market value of their outstanding shares is at $708.0 million.
  • Precision BioSciences (NASDAQ:DTIL) shares decreased by 18.32% to $13.07. The market value of their outstanding shares is at $53.1 million.
  • HeartBeam (NASDAQ:BEAT) shares fell 14.79% to $1.21. The market value of their outstanding shares is at $31.8 million.
  • MediciNova (NASDAQ:MNOV) shares fell 11.54% to $1.15. The company's market cap stands at $56.4 million.
  • BioSig Technologies (NASDAQ:BSGM) stock fell 10.23% to $0.43. The market value of their outstanding shares is at $4.0 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment